Price movement over the last 24 hours
Alcon AG vs Gemini Space Station Inc — how do they compare? Alcon AG trades at $66.64 (market cap $32.69B), while Gemini Space Station Inc trades at $4.22 (market cap $528.49M). The key difference: Alcon AG is far larger — about 61.9× Gemini Space Station Inc's market cap, and Alcon AG pays a 0.54% dividend while Gemini Space Station Inc pays none. Which is the better fit depends on your goals.
| ALC | GEMI | |
|---|---|---|
Market Cap | $32.69B | $528.49M |
Sector | Health | Technology |
52-Week High | $92.22 | $32.52 |
52-Week Low | $62.02 | $3.91 |
Enterprise Value | $36.28B | $518.47M |
Dividend Yield | 0.54% | — |
Signals from Pluang's Aura AI — not financial advice
ALC trades at $66.87, down 4.01% on the day, amid a mixed technical and fundamental backdrop. The stock exhibits a bullish technical signal overall, with moving averages supporting a positive trend, while oscillators remain neutral. Fundamentally, revenue growth is steady, reaching $10.40 billion in 2025, though net income margin compressed to 7.7%. Recent news highlights product innovation, including a collaboration with RxSight for adjustable PCIOLs, signaling ongoing R&D investment. Analyst sentiment is predominantly positive, with a consensus price target of $86.00 implying significant upside.
The outlook for ALC is cautiously optimistic, driven by new product launches and strategic partnerships that may fuel growth. However, risks include competitive pressures, macroeconomic headwinds, and margin compression. With a P/E of 40.92, the valuation appears rich relative to historical norms, requiring strong earnings delivery to justify current levels. Investors should weigh robust analyst buy ratings against execution risks and market volatility.
Gemini Space Station (GEMI) trades at $4.41, up 4.26% today, but remains in a bearish technical trend with significant fundamental challenges. The company reported a net loss of $582.81 million in 2025, with negative gross and net income margins, and has missed earnings expectations for three consecutive quarters. Recent news includes a $100 million investment from Winklevoss Capital but also multiple class-action lawsuits alleging securities law violations.
The outlook is highly speculative. Analyst consensus suggests modest upside to a $5.95 price target, but persistent losses, legal overhangs, and negative cash flow from operations pose substantial risks. Investment appeal hinges on the company's ability to monetize its super app strategy and achieve profitability, which remains uncertain.
Trailing returns across standard periods
Latest headlines on both assets
Alcon, headquartered in Fort Worth, Texas, is the global eyecare leader with a diverse portfolio in ophthalmology including contact lenses, eye drops, surgical equipment, and related surgical products. Novartis purchased Alcon from Nestle in 2010 and, following nine years as a Novartis subsidiary, the company was spun off as a public company in April 2019. The company reports five distinct segments: implantables (16% of revenue), consumables (31%), equipment (9%), contact lenses (27%), and ocular health (17%). The company is geographically diversified, with only about 40% of revenue from the U.S. market, and the firm has a strong presence in the European Union and Japan.
Read more on ALC →Gemini Space Station Inc is the parent company of the Gemini crypto ecosystem, founded by Cameron and Tyler Winklevoss. It operates as a regulated digital asset exchange and custodian, providing a platform for individuals and institutions to trade, store, and stake cryptocurrencies while serving as a trusted bridge between legacy finance and the decentralized web.
Read more on GEMI →